ImmunityBio, Inc. (NASDAQ: IBRX) has announced impressive financial results for the third quarter of 2026, highlighting a 53% year-over-year increase in net product revenue. The company also revealed expanded FDA approvals for its immunotherapy product ANKTIVA, marking a significant milestone in its growth strategy.

On November 9, 2026, ImmunityBio issued a press release detailing its financial performance for the three and nine months ended September 30, 2026. This update is crucial as it not only showcases the company's revenue growth but also its ongoing commitment to advancing cancer treatment solutions.

Background

ImmunityBio, Inc. is a commercial-stage immunotherapy company based in San Diego, California. The company operates within the biological products sector, specifically focusing on products that do not include diagnostic substances (SIC: 2836). ImmunityBio trades on the Nasdaq under the ticker symbol IBRX. Recent filings include an 8-K on November 9, 2026, detailing significant financial updates and business developments.

What the Filing Says

The filing disclosed that ImmunityBio's net product revenue for Q3 2026 reached $48.7 million, a 53% increase compared to the same quarter last year. The company attributed this growth to the continued adoption of ANKTIVA among U.S. urologists and strong market access. Additionally, the year-to-date revenue for 2026 stands at $143.6 million, reflecting a remarkable 92% increase year-over-year.

In terms of regulatory achievements, the FDA has expanded the approved indication for ANKTIVA to include adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). This approval is a significant boost for the company, as it now allows treatment for patients with high-grade papillary-only tumors. Furthermore, ImmunityBio announced that it has received approval for ANKTIVA in Israel, expanding its global reach to 35 countries.

Impact

The positive financial results and expanded approvals may have a considerable impact on various stakeholders, including investors, healthcare providers, and patients. The company's growth trajectory could influence competitors in the biological products sector, prompting them to reassess their strategies in immunotherapy and cancer treatment.

What's Next

Looking ahead, ImmunityBio is expected to continue its momentum with additional regulatory submissions and clinical trials. The filing does not specify what happens next, but the company is likely to focus on leveraging its recent successes to further enhance its market position.